(Q38444551)

3 September 2017

1 reference

title

Glutamatergic agents for schizophrenia: current evidence and perspectives (English)

1 reference

3 September 2017

1 reference

2

Christoph U Correll

1 reference

3 September 2017

Mathias Zink

1

1 reference

PubMed ID

25916667

3 September 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

Expert Review of Clinical Pharmacology

3 September 2017

1 reference

3 September 2017

8

1 reference

3 September 2017

3

1 reference

3 September 2017

335-352

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

3 September 2017

1 reference

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Polypharmacy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A systematic review and meta-analysis of recovery in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Attitudes towards psychiatric treatment and people with mental illness: changes over two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The nature of dopamine dysfunction in schizophrenia and what this means for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Past and present progress in the pharmacologic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine, GABA(B), and the treatment of resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

What are we looking for in new antipsychotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Emerging drugs for schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The endocannabinoid system and schizophrenia: links to the underlying pathophysiology and to novel treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Schizophrenia guidelines across the world: a selective review and comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine: more side effects but still the best antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Rediscovering catatonia: the biography of a treatable syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Mechanism of Action of Antipsychotic Medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Bupropion for depression in schizophrenia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic treatment modulates glutamate transport and NMDA receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Early life programming and neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

21 January 2018

Rethinking schizophrenia

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Receptor mapping: architecture of the human cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The validity of animal models of predisposition to depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Uncoupling dendrite growth and patterning: single-cell knockout analysis of NMDA receptor 2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Mechanism of differential control of NMDA receptor activity by NR2 subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Lamotrigine blocks repeated high-dose methamphetamine-induced behavioral sensitization to dizocilpine (MK-801), but not methamphetamine in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Topiramate antagonizes MK-801 in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of topiramate on the prepulse inhibition of the acoustic startle in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of pregabalin on behavioral alterations induced by ketamine in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pregabalin in the treatment of schizophrenic anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Augmentation with pregabalin in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Investigational drugs for anxiety in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pregabalin-Associated Increase of Clozapine Serum Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

D-serine and schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Gene knockout of glycine transporter 1: characterization of the behavioral phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Association study of polymorphisms in glycine transporter with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The therapeutic potential of glycine transporter-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Minocycline as adjunctive therapy for schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clinical potential of minocycline for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glutamate signaling in the pathophysiology and therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

AMPA receptor positive allosteric modulators: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glycine treatment of the risk syndrome for psychosis: report of two pilot studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

DARPP-32 mediates the actions of multiple drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The psychosis high-risk state: a comprehensive state-of-the-art review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Research in people with psychosis risk syndrome: a review of the current evidence and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Aripiprazole differentially regulates the expression of Gad67 and γ-aminobutyric acid transporters in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The role of serotonin receptors in the action of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Biological insights from 108 schizophrenia-associated genetic loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Effects of risperidone on glutamate receptor subtypes in developing rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Atypical antipsychotic olanzapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of dizocilpine (MK-801) into the inferior colliculus in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.1040393

10.1586/17512433.2015.1040393

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25916667